About Xencor
Xencor is a publicly listed company based in Monrovia (United States) founded in 1997. It operates as an engineering Antibodies to treat autoimmune disorders, asthma, allergic diseases and cancer. Xencor has raised $7.6 million across 3 funding rounds. The company has 250 employees. Its chief executive is Bassil I Dahiyat. Its website xencor.com draws about 22 thousand monthly visits. Xencor offers products and services including XmAb Platform, Bispecific Antibodies, and Cytotoxic Fc Domains. Its focus areas include Life Sciences, Immunotherapy, Antibody and Disease-Targeting. Its competitors include Moderna, Merck, Roivant Sciences, BeiGene and AbbVie and 5 more; 4 of its 10 listed competitors have raised funding.
Company details
Xencor is developing superior monoclonal antibody therapeutics optimized to treat autoimmune disorders, asthma and allergic diseases, and cancer. Its antibody engineering platform precisely alters the Fc domain (the stem of the antibody structure) to significantly enhance natural functions and performance. Its product pipeline includes XmAb5871, a monoclonal antibody that targets CD19 with its variable domain and uses the XmAb immune inhibitory Fc domain to target FcγRIIb, a receptor that inhibits B cell function current in Phase 2 for the treatment of rheumatoid arthritis and lupus XmAb7195 for AsthmaAllergy. Also, have preclinical stage antibodies for the treatment of different cancers.
- Headquarters Monrovia, United States
- Employees 250
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Website xencor.com
- Social LinkedIn X
- Legal Name Xencor, Inc.
- Annual Revenue$125.58 M (USD)13.65as on Dec 31, 2025
- Net Profit-$91.92 M (USD)60.48as on Dec 31, 2025
- EBITDA-$166.99 M (USD)-0.41as on Dec 31, 2025
- Total Equity Funding$7.6M (USD)
in 3 rounds
- Latest Funding Round$7.6M (USD), Series A
Jun 2013
- Employee Count250
Products & Services of Xencor
Xencor offers a comprehensive portfolio of products and services, including XmAb Platform, Bispecific Antibodies, and Cytotoxic Fc Domains.
Engineering platform for developing antibody therapeutics
Targeted treatments for cancer and immune disorders
Domains enhancing antibody drug efficacy in diseases
Funding Insights of Xencor
Xencor has successfully raised a total of $7.6M across 3 strategic funding rounds. The most recent funding activity was a Series A round of $7.6 million completed in June 2013. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $7.6M
- Total Rounds 3
- Last Round Series A — $7.6M
- First Round $6M
(Apr 2009)
All 3 funding rounds of Xencor with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2013 | $7.6M | Series A | – | – | – |
| Dec 2010 | $7.5M | Debt – Conventional | – | – | – |
| Apr 2009 | $6M | Debt – Conventional | – | – | – |
People of Xencor
142 people are tracked at Xencor (75 in leadership, 5 in board & advisors, 62 in team); the tracked headcount is 250.
| Name | Role | Group |
|---|---|---|
Bassil I Dahiyat | CEO & President | Leadership |
Jennifer Sandoz | VP, Human Resources | Leadership |
Katrina Bykova | Associate Director | Leadership |
Mitra Pejman | Associate Director, Clinical Contracts & Outsourcing | Leadership |
Azheny Zdeb | Director Of Pharmacovigilance And Drug Safety | Leadership |
Michael Minor | Senior Director, Program Leadership And Alliance Management | Leadership |
Mahrukh Yasin | Director Of Business Development | Leadership |
James Wieler | Director Antibody Discovery | Leadership |
Sophie Visonneau | Vice President, Head Of Clinical Operations | Leadership |
John J. Kuch | SVP & CFO | Leadership |
John R. Desjarlais | EVP, Research & Chief Scientific Officer | Leadership |
Rumana Rashid | Associate Director, Protein Science And Technology | Leadership |
Sher Karki | Executive Director | Leadership |
Juhi Firdos | Director | Leadership |
Nancy Valente | EVP & Chief Development Officer | Leadership |
Jitendra Kanodia | Vice President Head Of Translational | Leadership |
Michael Chiarella | Senior Director, Clinical Science | Leadership |
Jesse Palomino | Associate Director, Environmental,health And Safety | Leadership |
Ranee Dicarlo | Associate Director TMF Operations | Leadership |
Sheri Mayer | Senior Director, Human Resources Operations & Compliance | Leadership |
122 more people are available in the full profile.
Complete people profiles for Xencor
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Xencor
Xencor is a publicly listed company on the NASDAQ with ticker symbol XNCR in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date03 Dec 2013
- Listed onNASDAQ: XNCR
- Listed entityXencor, Inc.
- Exchange sectorHealth technology
- ISINUS98401F1057
- Share price$23.52 (-6.07% on the day) · 2026-10-13
- Market capitalisation$1.75B
- EPS (diluted, trailing year)$-2.17
- Volume (last session)2,425,957
Financials of Xencor
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $125.6M | -$91.9M | -$167.0M |
| 2024 | $110.5M | -$232.6M | -$166.3M |
| 2023 | $174.6M | -$133.1M | -$120.9M |
| 2022 | $164.6M | -$55.2M | -$72.2M |
| 2021 | $275.1M | $82.6M | $52.2M |
Detailed financial statements for Xencor
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Xencor
4 dated milestones of Xencor across 16 years, from founding to its latest funding, stage changes and deals.
- Founded Xencor is founded.
- Funding First funding round of $6.0M.
- Funding Latest funding round, Series A, of $7.6M.
- IPO Lists on the stock exchange (IPO).
Competitors of Xencor
Xencor has 10 listed competitors in our database, 4 of them funded. They include Moderna, Merck, Roivant Sciences, BeiGene and AbbVie, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| merck.com | 1891 | Kenilworth, United Kingdom | – | 781 | Pharmaceutical products are manufactured and marketed worldwide. | |
| roivant.com | 2014 | New York, United States | $1.3B | 662 | Therapeutics for neurology, oncology, rare, and endocrinology diseases are developed. | |
| beigene.com | 2010 | Cambridge, United States | $172M | 1,090 | Targeted and immune-oncology drugs for cancer treatment are developed. | |
| abbvie.com | 2012 | Chicago, United States | – | 8,667 | Biopharmaceutical research and drug development are conducted globally by AbbVie. | |
| gilead.com | 1987 | Foster, United States | – | 4,267 | Developer of medicines to treat HIV/AIDS, liver diseases, cancer & others | |
| lilly.com | 1876 | United States | – | 39,000 | Traditional pharmaceutical medicines are developed for multiple health fields. | |
| incyte.com | 1991 | Wilmington, United States | – | 1,387 | Small molecules are developed for cancer and skin disease treatments. | |
| vrtx.com | 1989 | United States | – | 5,400 | Developer of drugs for the treatment of multiple disorders | |
| ultragenyx.com | 2010 | Novato, United States | $135.1M | 837 | Therapeutics for rare and ultra-rare metabolic diseases are developed. |
Detailed competitors of Xencor
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Xencor
The website of Xencor (xencor.com) receives about 22.2K visits a month and ranks #2,563,685 among all websites worldwide, #3,512 in Biotechnology and Pharmaceuticals.
- Monthly visits22.2K
▲ 97.8% vs previous month
- Unique visitors3.4K
per month
- Global rank#2,563,685
among all websites
- Category rank#3,512
Health · Biotechnology and Pharmaceuticals
- Bounce rate61%
- Pages per visit1.4
- Average visit9 sec
- DevicesDesktop 58% · Mobile 42%
Websites whose visitors overlap most with Xencor. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| biocentury.com | 100% | 85.7K | #514,907 | View details | |
ir.macrogenics.com | ir.macrogenics.com | 99% | – | – | – |
gemacbio.com | gemacbio.com | 98% | – | – | – |
| xoma.com | 98% | 8K | #3,718,828 | View details | |
| zymogenetics.com | 98% | – | – | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 14 similar websites and full traffic analytics for Xencor
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 14 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Immunology & Cancer Therapeutics
10 companies that operate in the same segment as Xencor (Immunology & Cancer Therapeutics), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Antibody-based drugs are developed for autoimmune diseases and cancer treatment. | 2008 | Ghent, East Flanders, Belgium | USD 61.9 M | USD 1.41 B | 355 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | – | – | |
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Targeted therapies for cancer treatment are developed. | 2005 | Waltham, Massachusetts, United States | USD 198.29 M | USD 172.35 M | 270 | |
Treatments for anemia and fibrosis by exploiting connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF) biology. | 1993 | San Francisco, California, United States | USD 213.52 M | USD 29.62 M | 225 | |
Plasma-based biologics are developed for immune deficiency and infectious diseases. | 2005 | Ramsey, Minnesota, United States | USD 17.55 M | USD 510.17 M | 685 | |
Antibody drugs for cancer treatment are developed. | 2015 | Singapore, Singapore | USD 150 M | – | – | |
CAR T-cell and T-cell receptor immunotherapies for cancer are developed. | 2013 | Seattle, Washington, United States | USD 316.67 M | – | 520 | |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis. | 2003 | United States | USD 171.85 M | USD 102.48 M | 338 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Xencor
Complete news archive for Xencor
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Xencor
Xencor was founded in 1997 and raised its 1st funding round 12 years after it was founded.
Xencor is headquartered in Monrovia, United States. It is registered at Monrovia, California, United States.
Bassil I Dahiyat is the current CEO of Xencor.
Xencor is a funded company, having raised a total of $7.6M across 3 funding rounds to date. The company's 1st funding round was a Debt – Conventional of $6M, raised on Apr 2009.
Xencor has 250 employees.
Annual revenue of Xencor is $125.58M as on Dec 31, 2025.
Xencor is developing superior monoclonal antibody therapeutics optimized to treat autoimmune disorders, asthma and allergic diseases, and cancer. Its antibody engineering platform precisely alters the Fc domain (the stem of the antibody structure) to significantly enhance natural functions and performance. Its product pipeline includes XmAb5871, a monoclonal antibody that targets CD19 with its variable domain and uses the XmAb immune inhibitory Fc domain to target FcγRIIb, a receptor that inhibits B cell function current in Phase 2 for the treatment of rheumatoid arthritis and lupus XmAb7195 for AsthmaAllergy. Also, have preclinical stage antibodies for the treatment of different cancers.
Xencor's top competitors include Merck, Moderna and Roivant Sciences.
Xencor offers XmAb Platform, Bispecific Antibodies, and Cytotoxic Fc Domains.
Yes, Xencor is publicly traded on NASDAQ under the ticker symbol XNCR.